Related Experiment Video
Updated: Feb 18, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic
Gonda Fj Konings1,2, Karlijn Mc Cornel1,2, Sofia Xanthoulea1,2
1GROW - School for Oncology and Developmental Biology, Maastricht University, The Netherlands.
Abstract:
The enzyme type 1 17β-hydroxysteroid dehydrogenase (17β-HSD-1), responsible for generating active 17β-estradiol (E2) from low-active estrone (E1), is overexpressed in endometrial cancer (EC), thus implicating an increased intra-tissue generation of E2 in this estrogen-dependent condition. In this study, we explored the possibility of inhibiting 17β-HSD-1 and impairing the generation of E2 from E1 in EC using in vitro, in vivo, and ex vivo models. We generated EC cell lines derived from the well-differentiated endometrial adenocarcinoma Ishikawa cell line and expressing levels of 17β-HSD-1 similar to human tissues. In these cells, HPLC analysis showed that 17β-HSD-1 activity could be blocked by a specific 17β-HSD-1 inhibitor. In vitro, E1 administration elicited colony formation similar to E2, and this was impaired by 17β-HSD-1 inhibition. In vivo, tumors grafted on the chicken chorioallantoic membrane (CAM) demonstrated that E1 upregulated the expression of the estrogen responsive cyclin A similar to E2, which was impaired by 17β-HSD-1 inhibition. Neither in vitro nor in vivo effects of E1 were observed using 17β-HSD-1-negative cells (negative control). Using a patient cohort of 52 primary ECs, we demonstrated the presence of 17β-HSD-1 enzyme activity (ex vivo in tumor tissues, as measured by HPLC), which was inhibited by over 90% in more than 45% of ECs using the 17β-HSD-1 inhibitor. Since drug treatment is generally indicated for metastatic/recurrent and not primary tumor, we next demonstrated the mRNA expression of the potential drug target, 17β-HSD-1, in metastatic lesions using a second cohort of 37 EC patients. In conclusion, 17β-HSD-1 inhibition efficiently blocks the generation of E2 from E1 using various EC models. Further preclinical investigations and 17β-HSD-1 inhibitor development to make candidate compounds suitable for the first human studies are awaited. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Insights
Inhibiting the enzyme 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD-1) effectively blocks the production of active estrogen (17β-estradiol) from estrone in endometrial cancer models. This finding supports 17β-HSD-1 as a potential therapeutic target for endometrial cancer.
Area of Science:
- Endocrinology
- Oncology
- Biochemistry
Background:
- Type 1 17β-hydroxysteroid dehydrogenase (17β-HSD-1) is overexpressed in endometrial cancer (EC), increasing intra-tissue generation of 17β-estradiol (E2).
- This increased E2 production is implicated in the estrogen-dependent progression of EC.
Purpose of the Study:
- To investigate the inhibition of 17β-HSD-1 to impair E2 generation from estrone (E1) in EC.
- To evaluate the therapeutic potential of targeting 17β-HSD-1 in various EC models.
Main Methods:
- Generated EC cell lines with similar 17β-HSD-1 levels to human tissues.
- Utilized in vitro (cell culture), in vivo (chicken chorioallantoic membrane model), and ex vivo (patient tumor tissues) approaches.
- Employed High-Performance Liquid Chromatography (HPLC) for enzyme activity assessment and specific 17β-HSD-1 inhibitors.
Main Results:
- 17β-HSD-1 activity was successfully blocked by a specific inhibitor in EC cells.
- Inhibition of 17β-HSD-1 impaired E1-induced colony formation in vitro and E1-driven cyclin A upregulation in vivo.
- Ex vivo analysis confirmed 17β-HSD-1 enzyme activity in primary EC tissues, with significant inhibition observed in over 45% of samples.
Conclusions:
- 17β-HSD-1 inhibition effectively blocks E2 generation from E1 across diverse EC models.
- The study demonstrates the presence and inhibition of 17β-HSD-1 activity in primary and metastatic EC.
- Further preclinical development of 17β-HSD-1 inhibitors is warranted for potential human studies in EC treatment.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

